Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer

• Main Authors: N.Y.L. Ngoi (Author), V. Heong (Author), X.W. Lee (Author), Y.Q. Huang (Author), Y.L. Thian (Author), B.A. Choo (Author), D. Lim (Author), Y.W. Lim (Author), S.E. Lim (Author), A. Ilancheran (Author), R. Soong (Author), D.S.P. Tan (Author)
• Format: Book
• Published: Elsevier, 2018-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Optimal treatment for advanced cervical cancer after first line chemotherapy remains undefined. Immune checkpoint inhibition with pembrolizumab, a programmed cell death protein 1(PD-1) inhibitor, is under investigation. We analyzed the micro-environmental and molecular genetic profile of tumors from...